Nova Eye Medical Future Growth
Future criteria checks 6/6
Nova Eye Medical is forecast to grow earnings and revenue by 102.3% and 26.3% per annum respectively. EPS is expected to grow by 101.6% per annum. Return on equity is forecast to be 28.9% in 3 years.
Key information
102.3%
Earnings growth rate
101.6%
EPS growth rate
| Medical Equipment earnings growth | 16.0% |
| Revenue growth rate | 26.3% |
| Future return on equity | 28.9% |
| Analyst coverage | Low |
| Last updated | 25 Nov 2024 |
Recent future growth updates
Recent updates
We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth
Nov 04
Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%
Sep 22Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)
Aug 06Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward
Apr 18Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?
Mar 26News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts
Jan 19Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce
Dec 27We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate
Sep 03Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified
Apr 17Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?
Dec 16We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Aug 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 53 | 6 | 5 | 7 | 2 |
| 6/30/2026 | 42 | 1 | 0 | 2 | 2 |
| 6/30/2025 | 32 | -3 | -3 | -1 | 2 |
| 6/30/2024 | 23 | -9 | -8 | -8 | N/A |
| 3/31/2024 | 21 | -12 | -8 | -7 | N/A |
| 12/31/2023 | 19 | -14 | -7 | -6 | N/A |
| 9/30/2023 | 18 | -15 | -7 | -7 | N/A |
| 6/30/2023 | 17 | -15 | -8 | -7 | N/A |
| 3/31/2023 | 16 | -13 | -9 | -8 | N/A |
| 12/31/2022 | 15 | -11 | -10 | -9 | N/A |
| 9/30/2022 | 14 | -9 | -10 | -7 | N/A |
| 6/30/2022 | 13 | -7 | -10 | -5 | N/A |
| 3/31/2022 | 13 | -7 | -13 | -8 | N/A |
| 12/31/2021 | 13 | -6 | -16 | -11 | N/A |
| 9/30/2021 | 13 | -5 | -16 | -12 | N/A |
| 6/30/2021 | 13 | -4 | -15 | -13 | N/A |
| 12/31/2020 | 12 | -9 | -1 | 0 | N/A |
| 9/30/2020 | 13 | -10 | 2 | 3 | N/A |
| 6/30/2020 | 13 | -10 | 4 | 5 | N/A |
| 12/31/2019 | 16 | -6 | -4 | -1 | N/A |
| 9/30/2019 | 16 | -6 | -6 | -2 | N/A |
| 6/30/2019 | 16 | -7 | -8 | -4 | N/A |
| 3/31/2019 | 48 | -7 | -7 | -2 | N/A |
| 12/31/2018 | 49 | -6 | -6 | -1 | N/A |
| 9/30/2018 | 64 | -6 | -6 | 0 | N/A |
| 6/30/2018 | 79 | -5 | -6 | 1 | N/A |
| 3/31/2018 | 77 | -5 | N/A | -2 | N/A |
| 12/31/2017 | 75 | -5 | N/A | -4 | N/A |
| 9/30/2017 | 73 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 72 | -1 | N/A | -3 | N/A |
| 3/31/2017 | 72 | 1 | N/A | -1 | N/A |
| 12/31/2016 | 73 | 3 | N/A | 2 | N/A |
| 9/30/2016 | 73 | 3 | N/A | 3 | N/A |
| 6/30/2016 | 73 | 3 | N/A | 5 | N/A |
| 3/31/2016 | 70 | 3 | N/A | 6 | N/A |
| 12/31/2015 | 67 | 2 | N/A | 7 | N/A |
| 9/30/2015 | 65 | 2 | N/A | 7 | N/A |
| 6/30/2015 | 63 | 2 | N/A | 7 | N/A |
| 3/31/2015 | 61 | 1 | N/A | 5 | N/A |
| 12/31/2014 | 59 | 1 | N/A | 4 | N/A |
| 9/30/2014 | 57 | 1 | N/A | 3 | N/A |
| 6/30/2014 | 54 | 1 | N/A | 3 | N/A |
| 3/31/2014 | 51 | 0 | N/A | 2 | N/A |
| 12/31/2013 | 47 | -1 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EYE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: EYE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EYE is expected to become profitable in the next 3 years.
Revenue vs Market: EYE's revenue (26.3% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: EYE's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EYE's Return on Equity is forecast to be high in 3 years time (28.9%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nova Eye Medical Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Michael Youlden | MST Financial Services Pty Limited |
| Robin Morgan | Taylor Collison Limited |